Get the latest news on immunotherapy
February 23, 2021
NeoImmuneTech receives U.S. FDA Investigational New Drug Clearance for Pilot Study of NT-17 (efineptakin alfa) for Progressive Multifocal Leukoencephalopathy
February 22, 2021
Cemiplimab approved as front-line therapy for advanced NSCLC
February 22, 2021
FDA grants Fast Track Designation to GEN-1 immunotherapy for patients with advanced stage III or IV ovarian cancer
February 22, 2021
AstraZeneca to withdraw Imfinzi in advanced bladder cancer treatment in the U.S. after confirmatory trial showed no improvement of Imfinzi checkpoint inhibitor use over chemotherapy
February 20, 2021
Australian researchers identify protein linked to better patient responses to checkpoint inhibitor immunotherapy
February 19, 2021
Immunocore’s novel bispecific protein, tebentafusp, granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA for uveal melanoma
February 18, 2021
New trial funding for Nektar Therapeutics’ bempegaldesleukin drug paired with Merck’s pembrolizumab for squamous cell carcinoma of the head and neck
February 18, 2021
Study findings by researchers at Memorial Sloan Kettering Cancer Center suggest that blocking cancer cells’ use of sugar could increase the effectiveness of immunotherapy
February 18, 2021
Phase III OlympiA trial investigating effect of PARP inhibitor Lynparza shows positive results in adjuvant setting for patients with early breast cancer
February 17, 2021
Immunitas Therapeutics uses single-cell RNA-sequencing to identify the NK gene KLRB1 as a candidate inhibitory receptor on NK and T cells with applicability as a target in cancer immunotherapy
February 17, 2021
Research suggests that cosmetic lasers may make immune checkpoint inhibitors more effective in treating cancers with low mutation numbers
February 17, 2021
Phase 2 of neoadjuvant tavokinogene teleplasmid plus nivolumab study doses first patient with operable, locally or regionally advanced melanoma before surgery
February 16, 2021
Immunotherapy-docetaxel combinations show promise in metastatic castration-resistant prostate cancer
February 16, 2021
Study findings indicate promising use of cord blood-derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma
February 15, 2021
Ludwig Cancer Research study identified novel mechanism for cancer immunotherapy using cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade to disable suppressive immune cells
February 15, 2021
Study from the University of Pittsburgh School of Medicine suggests MCT1 inhibition drugs may boost effects of cancer immunotherapy
February 15, 2021
FDA approves nivolumab-cabozantinib as first-line treatment of advanced renal cell carcinoma
February 11, 2021
Repertoire Immune Medicines and Dana-Farber Cancer Institute announce new research collaboration aimed to identify novel tumor antigen targets relevant to HPV+ head and neck tumors
February 10, 2021
Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
February 10, 2021
FDA ODAC votes against recommending Keytruda for breast cancer
February 10, 2021
Case study analyzes successful Nivolumab treatment for head and neck squamous cell carcinoma after allogeneic bone marrow transplantation
February 10, 2021
FDA approves the chimeric antigen receptor (CAR) T-cell therapy Breyanzi, lisocabtagene maraleucel, for large B-cell lymphomas
February 10, 2021
Targovax and Papyrus will run pre-clinical research to evaluate the feasibility of combining Oncolytic Virus (ONCOS) and Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML) tumor suppressor technology
February 10, 2021
Smectite promotes probiotic biofilm formation in gut for cancer immunotherapy
February 10, 2021
Study links greater survival benefits from immunotherapy in Black men to increased tumor plasma cells
February 8, 2021
Bristol Myers Squibb’s Opdivo reduces recurrence of muscle-invasive urothelial carcinoma
February 8, 2021
4D pharma announces new clinical trial using combined MRx0518, a Live Biotherapeutic product, and BAVENCIO monotherapies for locally advanced or metastatic urothelial carcinoma
February 8, 2021
Combination of Keytruda and Yervoy fails to prolong survival and delay disease progression of advanced non-small cell lung cancer
February 8, 2021
Joint radionuclide and immunotherapy approach for prostate cancer effective in mice
February 8, 2021
Multigene variant profiling assay to guide targeted immunotherapy selection in solid tumors
January 25, 2021
Korea-based microbiome technology company, Genome & Company, utilizes microbiome-based drugs in combination with Merck and Pfizer’s Bavencio in new U.S. clinical trials
January 13, 2021
FDA Grants Fast Track Designations in Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
January 13, 2021
Istari wins orphan drug designation for melanoma therapy
January 11, 2021
Age May Not Impact Outcomes from Metastatic Renal Cell Carcinoma Treatment Despite Increased Toxicity in Older Patients
January 9, 2021
A Drug Indication Is Pulled From the Market: Now What?
January 8, 2021
Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports
January 8, 2021
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma
January 7, 2021
Eganelisib/Nivolumab Shows Encouraging Efficacy in Advanced, Metastatic Urothelial Carcinoma
January 4, 2021
Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer
January 2, 2021
Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome
December 23, 2020
The Society for Immunotherapy of Cancer (SITC) recommends actions for patients concerning SARS-CoV-2 vaccination and cancer immunotherapy
December 10, 2020
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium
December 9, 2020
Stellar Results from Kintor’s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer
December 7, 2020
Researchers identify potential drug combination to treat uveal melanoma
December 7, 2020
FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer
December 7, 2020
Activity of Brentuximab Vedotin Plus Nivolumab Clinically Meaningful for Subset of Patients with HL
December 6, 2020
Personalized cancer vaccine shows promise in combination with pembrolizumab in HNSCC (presented at SITC)
December 4, 2020
Nivolumab demonstrates survival benefits in the adjuvant setting (indirect treatment comparison study presented at SITC)
December 3, 2020
Neoadjuvant Nivolumab Safe for Nonmetastatic High-Risk RCC
December 2, 2020
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
December 2, 2020
ONCOS-102 plus pembrolizumab induces responses in anti-PD1-refractory melanoma
November 30, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
November 13, 2020
Bempegaldesleukin plus nivolumab showed durable benefit in metastatic melanoma (SITC 2020)
November 13, 2020
Pembrolizumab approved in triple-negative breast cancer (TNBC)
November 8, 2020
Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma
November 7, 2020
TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential
November 6, 2020
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
November 6, 2020
NICE rules nivolumab is not cost effective for use on NHS
November 3, 2020
Studies Find Connection Between Age and Melanoma Treatment Resistance
November 2, 2020
Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels
October 31, 2020
Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC
October 19, 2020
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
September 21, 2020
ESMO 2020 Virtual Conference: Immunomedics wows ESMO with breast cancer data reveal
September 21, 2020
ESMO 2020 Virtual Conference: Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
September 21, 2020
ESMO 2020 Virtual Conference: QUANTITATIVE SUMMARY OF QOL DATA CONFIRMS IMMUNE CHECKPOINT INHIBITOR THERAPY IS GENERALLY WELL-TOLERATED
September 21, 2020
ESMO Virtual Conference 2020: IMMUNOTHERAPY IS BENEFICIAL IN GASTRIC AND ESOPHAGEAL CANCERS, STUDIES SHOW
September 20, 2020
ESMO 2020 Virtual Conference: PEMBROLIZUMAB DELIVERS CLINICAL BENEFIT IN SELECTED HISTOTYPES OF RARE SARCOMA
September 19, 2020
ESMO 2020 Virtual Conference: Results for Sacituzumab govitecan-hziy in breast and bladder support this antibody-drug conjugate
September 19, 2020
ESMO Virtual Conference 2020: Results from IO Therapy for Triple Negative Breast Cancer
September 19, 2020
ESMO Virtual Conference 2020: Nivolumab and cabozantinib effective in first-line treatment for metastatic kidney cancer
September 18, 2020
Durvalumab demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
September 18, 2020
2020 ESMO Virtual Congress 2020: Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
September 17, 2020
ESMO Virtual Congress 2020: Nivolumab + Ipilimumab vs. Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma in CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients without Nephrectomy
September 14, 2020
Adjuvant Opdivo shows promise in Esophageal-GEJ Cancer Patients
September 12, 2020
Higher Microbial Diversity May Be Associated with Better Outcomes in Patients with RCC
September 10, 2020
Validation of AI tools for cancer immunotherapy may be a step closer
September 10, 2020
Nivolumab/ipilimumab dual immune-checkpoint blockade active in mCRPC
September 8, 2020
Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC
August 20, 2020
Merck’s oral cancer drug targeting STING boosts PD-1 immune blockade in mice
August 20, 2020
Immunotherapy Combo Shows Positive Results for Mesothelioma
August 19, 2020
Young Female Patients Have Low Response Rates to Immunotherapy
August 19, 2020
Pembrolizumab regimen extends survival in advanced esophageal cancer
August 19, 2020
Greater Diversity in Gut Microbiome Associated with Better Cancer Immunotherapy Outcomes
August 18, 2020
New App Helps Clinicians Manage Checkpoint Inhibitor AEs
August 15, 2020
CAR-NK Cell Immunotherapy Shows Promise
July 30, 2020
FDA Approves Atezolizumab Targeted Therapy Triple Combo for BRAF V600 Unresectable or Metastatic Melanoma
June 29, 2020
Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer
June 29, 2020
FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
June 27, 2020
Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure
June 25, 2020
Noadjuvant Melanoma Combo Improves RFS in Macroscopic Melanoma
June 24, 2020
FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma
June 9, 2020
Dramatic Drop in Skin Cancer Referrals During COVID-19 Crisis
June 8, 2020
New findings with immunotherapy in the adjuvant setting for Merkel Cell Carcinoma
June 8, 2020
Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study
June 8, 2020
Personalized treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits
June 3, 2020
Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1
May 28, 2020
Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy
May 28, 2020
Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations
May 18, 2020
FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup
April 28, 2020
FDA Approves Every-6-Week Pembrolizumab Dosage
April 27, 2020
Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen
April 27, 2020
Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma
April 10, 2020
Checkpoint Combo Runs the Table in Early CRC
March 31, 2020
Skin Cancer Education & Research Foundation Launches New Website – A New Resource for the Fight Against Skin Caner.
March 25, 2020
Seattle Cancer Care Alliance, at the epicenter of the US epidemic, provides insights for cancer care during the evolving the COVID-19 crisis.
February 12, 2020
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC)
February 12, 2020
Dealing with Coronavirus (COVID-19): Recommendations from the CDC
February 11, 2020
Seattle Genetics, Astellas, and Merck Hit a Bladder Cancer Bullseye
February 11, 2020
Jounce Using New Predictive Biomarker to Select Patients for Upcoming Phase II Immunotherapy Trial
February 10, 2020
Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer
February 3, 2020
First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors
January 26, 2020
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
January 23, 2020
FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancers
January 15, 2020
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
January 13, 2020
Influenza Vaccines Triggers Immune System Response in Tumors
January 12, 2020
Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients
January 11, 2020
Early-Stage Leukemia Vaccine Study Reports 80% Survival Rate
January 8, 2020
FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
January 8, 2020
U.S. cancer death rate sees largest yearly drop
January 3, 2020
Tislelizumab-Chemo Combo Induces Durable Responses in Patients with Stomach, Esophagus Cancers, Trial Data Show
December 13, 2019
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
December 9, 2019
ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma
December 9, 2019
Nivolumab shows promise in ‘wide variety’ of mismatch repair-deficient cancers
December 8, 2019
Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission
December 8, 2019
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
December 8, 2019
Hyperprogression Halts Study of Nivolumab in Peripheral T-Cell Lymphomas
December 8, 2019
Speeding Access To New And Innovative Cancer Treatments
November 20, 2019
Opdivo/Yervoy combo for melanoma fails in key patient population
November 1, 2019
5-year survival data positive for nivolumab-based regimens in advanced melanoma
November 1, 2019
STING pathway may be key to tumor cell recognition by immune cells
October 29, 2019
ASDS Steering committee develops evidence-based consensus on cSCC staging, workup, treatment
October 28, 2019
Managing Hematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors
October 28, 2019
Nivolumab improves survival in non-small cell lung carcinoma, study results suggest
October 28, 2019
IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer
October 28, 2019
Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds
September 27, 2019
Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor
September 27, 2019
Systemic immune response in squamous cell carcinoma of the head and neck: A comparative concordance index analysis
September 26, 2019
Tasmanian devil research could help tackle immunotherapy resistance
September 26, 2019
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
September 26, 2019
IL-10-based therapy shows promise when used in combination with anti-PD1 agents in lung and RCC
September 26, 2019
Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab
September 26, 2019
Boost in Survival Rates for Younger Patients With Melanoma Attributed to Immunotherapy Agents
September 4, 2019
Nivolumab more effective versus investigator’s choice in younger vs older patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
September 4, 2019
TGF-Beta may be a predictive biomarker for response to pembrolizumab in HCC
September 3, 2019
Pooled Analysis Shows Triple OS with Nivolumab in Advanced NSCLC
August 30, 2019
Myasthenia gravis induced by avelumab
August 22, 2019
Anti-TNF therapy given concurrently with ICI therapy may be beneficial in patients with GI irAEs
August 16, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled, phase 3 trial
August 16, 2019
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma
August 16, 2019
ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show
August 14, 2019
ICIs may trigger rare form of bullous pemphigoid
July 27, 2019
Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC
July 26, 2019
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
July 25, 2019
Update on Frontline Nivolumab/Ipilimumab Combo Demonstrates Positive OS Results in PD-L1+ NSCLC
July 19, 2019
Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says
July 12, 2019
Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma
July 10, 2019
Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors
June 19, 2019
Implementation of a Multidisciplinary Approach for Managing Immunotherapy-Related Toxicities
June 18, 2019
Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show
June 18, 2019
Phase 1 Study Demonstrates Safety of Pembrolizumab in Patients With HIV and Advanced Cancer
June 18, 2019
Keytruda approved for metastatic small cell lung cancer that has progressed after previous treatment
June 4, 2019
Alternate Doses of Ipilimumab Show Similar Results in Advanced Melanoma
May 27, 2019
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
May 22, 2019
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
May 17, 2019
Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
May 16, 2019
First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals
May 16, 2019
Immunotherapy response differs by EFGR mutation subtype
May 16, 2019
FDA approves Bavencio with Inlyta for patients with advanced renal cell carcinoma
May 14, 2019
Adopted cell transfer therapy being studied in sarcoma
May 2, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
May 1, 2019
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
April 30, 2019
Keytruda-Inlyta combo approved by FDA for untreated advanced kidney cancer
April 22, 2019
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
April 16, 2019
Clinical Trial in Ireland Investigates Cellular Immunotherapy as Treatment for Two Autoimmune Liver Diseases
April 15, 2019
The Gut Microbiome & Cancer Immunotherapy
April 15, 2019
Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma
April 15, 2019
Cancers ‘change spots’ to avoid immunotherapy
April 12, 2019
TKI-Immunotherapy Combinations Push the Envelope in Frontline RCC
April 11, 2019
First Off-the-Shelf Immunotherapy Clinical Trial Launched
April 11, 2019
FDA Expands Keytruda Indication for First-Line Treatment of Non-Small Cell Lung Cancer
April 10, 2019
Comorbidities Result in Fewer Patients in Clinical Trials
April 10, 2019
Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
April 10, 2019
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
April 9, 2019
Incysus Therapeutics gets FDA approval for brain cancer treatment trial
April 9, 2019
SWOG cancer research network study opens window into immune microenviroment
April 9, 2019
The changing landscape of diagnostic biomarkers: Exploring the one-biomarker-per-drug paradigm in oncology
April 8, 2019
Cancer ‘vaccine’ shows promise in human trial of lymphoma patients
April 8, 2019
Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for Two Autoimmune Liver Diseases
April 7, 2019
Researchers Develop “Swiss Army Knife” Immunotherapy to “Kick and Kill” HIV
April 5, 2019
Fecal transplants could help patients on cancer immunotherapy drugs
April 2, 2019
Gut microbes can spur immune system to attack cancer
April 1, 2019
UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells
April 1, 2019
Despite research boom, few immunotherapy studies targeting pancreatic cancer
April 1, 2019
How immune cells help tumors escape body’s defenses
March 31, 2019
AACR 2019 Research Roundup: Pancreatic Cancer Immunotherapy, Prostate Cancer Drug Resistance, Insight into Inherited Cancer Mutations
March 30, 2019
ETH researchers take major step towards personalized cancer immunotherapy
March 29, 2019
Combining DNA Damage Response Inhibitors with Immunotherapy Boosts SCLC Clearance, Mouse Study Shows
March 29, 2019
Immunotherapy for Pre-Cancerous Lesions May Reduce Skin Cancer Risk Over Time
March 28, 2019
Harnessing T-cell “stemness” could enhance cancer immunotherapy
March 28, 2019
Better Muscle Mass Linked to Improved Immunotherapy Response
March 28, 2019
New study confirms EpCAM as promising target for cancer immunotherapy
March 24, 2019
Bladder Cancer Guidelines Showcase Advent of Immunotherapy
March 22, 2019
FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC
March 21, 2019
Immunotherapies for Staphylococcus aureus
March 21, 2019
Imugene gains guidance for KEY-Vaxx Immunotherapy development
March 21, 2019
New U.K. Partnership Aims To Improve Access Immunotherapy For Cancer Patients
March 21, 2019
OHSU Knight Cancer Institute Throws Out Old System Of Clinical Trials
March 20, 2019
EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC
March 18, 2019
Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy
March 15, 2019
TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy
March 13, 2019
Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway
March 13, 2019
Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals
March 12, 2019
Harness the immune system to fight colon cancer
March 11, 2019
FDA Approves Tecentriq-Abraxane Combo as First Immunotherapy Regimen for Breast Cancer
March 11, 2019
Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials
March 8, 2019
Precision drugs could unmask cancers to immune system and boost effects of immunotherapy
March 8, 2019
FDA approves 1st immunotherapy drug to treat breast cancer
March 8, 2019
Immunotherapy in Bladder Cancer
March 8, 2019
More News! Targeting tuberculosis, light-activated drugs, cancer immunotherapies and more
March 8, 2019
Recognizing Endometrial Tumor Immune Features Is Key to Treatment Success
February 26, 2019
Patient-Reported Side Effects: A Crucial Part of Cancer Clinical Trials
February 26, 2019
A Growing Focus on Rare Cancers in Phase I Trials
February 26, 2019
Expert Addresses Toxicity Management for Approved CAR T-Cell Therapies
February 21, 2019
A New Treatment in Oral Immunotherapy Can Relieve Food Allergies, But Few Doctors Offer It
February 21, 2019
Merck in $300M Immune Design boost to Keytruda
February 19, 2019
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
February 13, 2019
Keytruda combo outshines Opdivo in kidney cancer
February 13, 2019
Positive Results Reported in Phase 1 Trial of Bavencio for Malignant Mesothelioma
February 13, 2019
Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma
February 12, 2019
Tuberculosis—Inhibiting host cell death with immunotherapy
February 12, 2019
Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients
February 12, 2019
Merck and Pfizer combination therapy improves kidney cancer survival
February 11, 2019
Merck Drug Found to Extend Lives of Brain-Cancer Patients
February 11, 2019
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
February 8, 2019
GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses
February 7, 2019
Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
February 6, 2019
FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer
February 5, 2019
Phase 1b Trial of ADCT-301 in Advanced Solid Tumors Doses First Patient
February 4, 2019
Emerging Immunotherapy Approaches For Urothelial Cancer
February 1, 2019
Tumors with More Mutations Respond Better to Immunotherapy, Study Suggests
January 31, 2019
FDA Expands Alimta Approval for Use With Immunotherapy and Chemo in Lung Cancer
January 31, 2019
Lung-MAP Trial Opens Enrollment to Patients With All Types of NSCLC
January 29, 2019
Brahmer Highlights Immunotherapies in the Pipeline for NSCLC
January 29, 2019
Could an immunotherapy treatment from Israel cure cancer?
January 29, 2019
Clinical trials offer opportunity for breakthroughs in cancer treatment; increased participation is key
January 29, 2019
CAR T Cells Get an Invisibility Cloak
January 28, 2019
Blocking pro-fibrosis pathway may improve immunotherapy of metastatic breast cancer
January 25, 2019
Immunotherapy Drug Avelumab Could Extend Survival for Patients with Unresectable Mesothelioma
January 24, 2019
Ongoing Study Looks to Bring Immunotherapy to Presurgical Setting in HCC
January 17, 2019
Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
1/11/2019
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
1/11/2019
Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer
1/9/2019
Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer
1/9/2019
FDA OKs Phase 2 Trial of AE37-Keytruda Combo in Metastatic Triple-negative Breast Cancer
1/9/2019
Does the Cost Outweigh the Benefit for CAR T-Cell Therapy?
1/9/2019
New clinical trial highlights haNK cell therapy in combination with IL-15 superagonist N-803 and avelumab
1/8/2019
Immune to cancer’s return? The day could be coming
1/7/2019
AVID200, which reverses immunosuppression to enhance sensitivity to checkpoint blockade, enters phase I trial
12/20/2018
AZ/Merck & Co get new US use for ovarian cancer drug
12/19/2018
Advanced melanoma trial when Keytruda alone is not enough
12/19/2018
Keytruda Seen as ‘Kinder’ and Superior to Standard Therapies for Advanced Head and Neck Cancer Patients in Phase 3 Trial
12/18/2018
Researchers identify ways breast cancer avoids immune system detection
12/18/2018
Metal chemotherapy drugs boost the impact of immunotherapy in cancer
12/18/2018
Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients
12/14/2018
AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia
12/6/2018
FDA approves Genentech drug for lung cancer
11/27/2018
Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
11/27/2018
Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows
11/26/2018
Nivolumab/Ipilimumab Combo Misses Primary Endpoint in Phase III SCLC Trial
11/26/2018
Avelumab Fails to Meet Primary Endpoints in Phase III Ovarian Cancer Trial
11/25/2018
Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential
11/21/2018
Durable Responses Seen With Atezolizumab in Advanced Alveolar Soft Part Sarcoma
11/6/2018
CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
11/5/2018
Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma
10/18/2018
Antiangiogenics and Immunotherapy Combos Show Promising Activity in Solid Tumors
10/17/2018
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
10/05/2018
MEDI0457 with Anti-PD-1 Therapy Shows Promise in Treating HPV-associated Head and Neck Cancer
10/04/2018
Immunotherapy Pioneers Win Nobel Prize for Research on Checkpoint Inhibitors
10/01/2018
Case study shows metastatic urothelial carcinoma patient with gastritis infection after receiving atezolizumab then pembrolizumab
09/28/2018
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
10/24/2017